Why AI matters at this scale

Syneos Health is a leading global contract research organization (CRO) and biopharmaceutical solutions company formed through a merger. It provides integrated clinical development and commercial outsourcing services to help biopharma clients bring therapies to market. With over 10,000 employees, it manages vast amounts of structured and unstructured data from hundreds of clinical trials, commercial engagements, and real-world evidence sources.

At this enterprise scale in a data-intensive sector, AI is not a luxury but a strategic imperative for maintaining competitive advantage. The core business challenges—lengthy and expensive clinical trials, inefficient patient recruitment, and complex commercial launches—are fundamentally data problems. Large CROs like Syneos possess the critical mass of data required to train effective AI models. Implementing AI can directly translate to faster trial cycles, reduced operational costs, higher-quality data, and more successful commercial outcomes for clients, creating a compelling value proposition for both Syneos and its customers.

Concrete AI Opportunities with ROI Framing

1. Optimizing Clinical Trial Design & Recruitment: AI algorithms can analyze historical trial data, real-world evidence, and genomic databases to optimize protocol design and predict the most viable patient populations and clinical trial sites. This reduces costly protocol amendments and cuts patient recruitment time—a major bottleneck. The ROI is direct: shorter trial durations mean lower operational costs for Syneos and faster time-to-market for clients, improving win rates for new business.

2. Automating Data Management & Compliance: Natural Language Processing (NLP) can automate the extraction and coding of data from case report forms, medical literature, and adverse event reports. This reduces manual labor, minimizes transcription errors, and accelerates database lock and regulatory submission timelines. The ROI manifests in significant labor cost savings, improved data quality (reducing costly queries), and the ability to handle higher volumes of work without linear staff increases.

3. Enhancing Pharmacovigilance & Risk Monitoring: Machine learning models can continuously monitor integrated data streams for early safety signal detection and predict site-level risk during trials. This enables a shift from periodic, on-site monitoring to a centralized, risk-based approach. The ROI includes reduced travel and monitoring costs, proactive risk mitigation (avoiding costly trial delays or failures), and strengthened client trust through enhanced safety surveillance.

Deployment Risks Specific to Large Enterprises (10,001+)

Deploying AI at Syneos's scale involves navigating significant risks. First, regulatory and compliance risk is paramount. Any AI tool used in clinical data analysis or safety reporting must be rigorously validated to meet FDA, EMA, and other global health authority standards, requiring substantial investment in validation frameworks. Second, data integration and silo risk is high. Syneos likely operates on a complex legacy tech stack with data scattered across acquisitions, client systems, and therapeutic areas. Creating a unified data foundation for AI is a major technical and organizational challenge. Third, change management and skill gap risk is substantial. Embedding AI-driven workflows into the practices of thousands of clinical and commercial professionals requires extensive training and may face cultural resistance. Finally, client confidentiality and data privacy risk is critical. AI models trained on pooled client data must be architected to ensure strict data segregation and compliance with global privacy laws like GDPR and HIPAA, adding layers of complexity to model development and deployment.